Commentary-1 (Research Highlights: USP30 Regulates the Mitophagy-Mediated Neuroprotection in Parkinson’s Disease)

E-ISSN： 1996-3181|13|10|1633-1634

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.13, Iss.10, 2014-12, pp. : 1633-1634

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Commentary-1 (Research Highlights: Olfactory Dysfunction in Parkinson’s Disease)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1079-1080

Bentham Science Publishers

Access to resources Recommend Favorite

Commentary 1 (Research Highlights: Parkinson's Disease and -Synuclein: Passing it on)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 1, 2013-02 ,pp. : 2-2

Bentham Science Publishers

Access to resources Recommend Favorite

Mitochondria: Prospective Targets for Neuroprotection in Parkinson’s Disease

Current Pharmaceutical Design, Vol. 20, Iss. 35, 2014-10 ,pp. : 5558-5573

Bentham Science Publishers

Access to resources Recommend Favorite

Commentary: Research Highlights ATF4: The Perpetrator in Axonal-Mediated Neurodegeneration in Alzheimer's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 9, 2014-11 ,pp. : 1483-1484

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotection for Parkinson’s disease: a new approach for a new millennium

By Drukarch Benjamin van Muiswinkel Freek L

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 10, 2001-10 ,pp. : 1855-1868

Informa Healthcare

Access to resources Recommend Favorite